Morgan Stanley notes that Cytokinetics (CYTK) released an 8-K providing a brief update regarding the regulatory status of aficamten for the treatment of obstructive hypertrophic cardiomyopathy, which has a PDUFA goal date of September 26. Overall, the firm views the update as “positive, but incremental” as some may have expected the FDA to hold an AdCom to discuss a potential Risk Evaluation and Mitigation Strategy. The firm has an Overweight rating and $67 price target on Cytokinetics shares.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>